View Entire Collection
By Clinical Topic
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, March 9 (HealthDay News) -- Oral anticoagulation (OAC)-treated patients with high levels of von Willebrand factor (VWF) have elevated risks of bleeding complications and cardiovascular and all-cause mortality, according to a study published in the March issue of the Journal of Internal Medicine.
Marcus Lind, M.D., of Umeå University Hospital in Sweden, and associates conducted a longitudinal study of 719 patients receiving OAC treatment to evaluate the link between VWF plasma levels and risk of bleeding complications, cardiovascular death, and all-cause mortality.
During 4.2 years of follow-up, the researchers identified 113 cases of clinically relevant bleeding and 73 cases of major bleeding; and there were 161 deaths, including 110 attributed to cardiovascular disease. There was a significantly increased risk of bleeding complications for patients in the highest tertile of VWF (hazard ratio [HR] for major bleeding, 2.53; HR for clinically relevant bleeding, 2.19). VWF was significantly associated with cardiovascular and all-cause mortality (HR, 1.68 and 1.77, respectively). These findings were significant after adjusting for age, high-sensitivity C-reactive protein, and creatinine.
"Our findings imply that the use of VWF as a risk marker for thromboembolic events is complicated by the association of VWF with bleeding complications," the authors write.
Full Text (subscription or payment may be required)
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top